natgillin/translations-raw huggingface dataset:
However, these two studies found that Altargo was not sufficiently effective in the treatment of abscesses (cavities containing pus) or of infections known or likely to be caused by MRSA. 
Vendar pa se je v teh dveh študijah izkazalo, da zdravilo Altargo ni bilo dovolj učinkovito pri zdravljenju abscesov (ognojkov) ter okužb, za katere je znano ali verjetno, da so jih povzročili sevi MRSA.
Altargo is an antibiotic medicine. 
Zdravilo Altargo je antibiotik.
What benefit has Altargo shown during the studies? 
Kakšne koristi je zdravilo Altargo izkazalo med raziskavami?
It can be used to treat impetigo (a skin infection causing crusting scabs), and small infected lacerations (cuts), abrasions (grazes) and wounds that have been sutured (stitched). 
Lahko se uporablja za zdravljenje impetiga (okužbe kože, ki povzroča skorjaste kraste) ter okuženih manjših raztrganin (vreznin), odrgnin in zašitih ran.
Two studies were carried out in patients with impetigo. 
Dve študiji sta bili izvedeni pri bolnikih z impetigom.
It is applied onto the affected area as a thin layer twice a day for five days. 
Na prizadeti predel kože se nanese tanko plast zdravila dvakrat na dan, pri čemer celotno zdravljenje traja pet dni.
However, it may be used to treat infections caused by other types of Staphylococcus aureus. 
Lahko pa se uporablja za zdravljenje okužb, ki jih povzročajo drugi sevi Staphylococcus aureus.
The Committee recommended that Altargo be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Altargo odobri dovoljenje za promet z zdravilom.
For the treatment of infected skin wounds, Altargo and cefalexin had similar response rates: when the results of both skin wound studies were taken together, around 90% of both groups of patients responded to treatment. 
Pri zdravljenju okuženih kožnih ran sta bili stopnji odziva na zdravilo Altargo in cefaleksin podobni: ocena kombiniranih rezultatov obeh študij kožnih ran je pokazala, da se je na zdravljenje odzvalo približno 90 % bolnikov iz obeh skupin.
Prescribers should consider official guidance on the 
Zdravniki, ki predpisujejo zdravilo, morajo upoštevati uradne smernice o uporabi
Altargo should not be used to treat infections known or thought likely to be due to methicillin-resistant Staphylococcus aureus (MRSA), as it may not work against this type of infection. 
Zdravila Altargo se ne sme uporabljati za zdravljenje okužb, za katere je bilo ugotovljeno ali pri katerih obstaja sum, da so jih povzročili sevi Staphylococcus aureus (MRSA), odporni na meticilin, ker mazilo morda ne bo učinkovito proti tej vrsti okužbe.
The full list of bacteria against which Altargo is active can be found in the Summary of Product 
Celoten seznam bakterij, proti katerim je zdravilo Altargo učinkovito, najdete v Povzetku glavnih značilnosti zdravila.
The most common side effect with Altargo (seen in between 1 and 10 patients in 100) is irritation at the site of application. 
Najpogostejši neželeni učinek zdravila Altargo (opažen pri 1 do 10 bolnikih izmed 100) je draženje na mestu nanosa.
How has Altargo been studied? 
Kako je bilo zdravilo Altargo raziskano?
Altargo was at least as effective as fusidic acid, with 314 (99.1%) of 317 and 141 (94.0%) of 150 patients, respectively, responding to treatment. 
Zdravilo Altargo je bilo vsaj tako učinkovito kot fusidinska kislina, saj se je na zdravljenje odzvalo 314 (99,1 %) od 317 bolnikov, pri fusidinski kislini pa 141 (94,0 %) od 150 bolnikov.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) ALTARGO EPAR summary for the public 
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) ALTARGO
In patients with impetigo, Altargo was more effective than placebo, with 119 (85.6%) of the 139 patients using Altargo and 37 (52.1%) of the 71 using placebo responding to treatment. 
Pri bolnikih z impetigom je bilo zdravilo Altargo učinkovitejše od placeba, saj se je na zdravljenje odzvalo 119 (85,6 %) od 139 bolnikov, ki so jemali zdravilo Altargo, in 37 (52,1 %) od 71 bolnikov, ki so jemali placebo.
Altargo should not be used in people who may be hypersensitive (allergic) to retapamulin or any of the 
Zdravila Altargo ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) retapamulin ali katerokoli drugo sestavino zdravila.
The active substance in Altargo, retapamulin, is an antibiotic belonging to the ‘pleuromutilin' class. 
Zdravilna učinkovina zdravila Altargo, retapamulin, je antibiotik iz skupine „pleuromutilinov“.
compared the effects of five days' treatment with Altargo to those of cefalexin (an oral antibiotic medicine): two studies were carried out in a total of 1,918 patients with infected skin wounds, and the final study was carried out in 545 patients with infected dermatitis (skin inflammation). 
V ostalih treh študijah so učinke petdnevnega zdravljenja z zdravilom Altargo primerjali z učinki cefaleksina (peroralnega antibiotika): dve študiji sta bili izvedeni s skupno 1.918 bolniki z okuženimi kožnimi ranami, končna študija pa je bila izvedena s 545 bolniki z infekcijskim dermatitisom (kožnim vnetjem).
Altargo is an ointment that contains the active substance retapamulin. 
Zdravilo Altargo je mazilo, ki vsebuje zdravilno učinkovino retapamulin.
The first compared the effects of five days' treatment with Altargo to those of placebo (a dummy treatment) in 213 patients, and the second compared Altargo to fusidic acid (another antibiotic ointment) in 519 patients. 
zdravljenja z zdravilom Altargo primerjali z učinki placeba (zdravila brez zdravilne učinkovine) pri 213 bolnikih, v drugi pa so učinke zdravila Altargo primerjali z učinki fusidinske kisline (drugega antibiotičnega mazila) pri 519 bolnikih.
The full EPAR for Altargo can be found here. 
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Altargo je na voljo tukaj.
The other three studies 
V prvi so učinke petdnevnega
The treated area can be covered with a sterile bandage or gauze dressing. 
Po nanosu mazila lahko prizadeti predel obvežete s sterilno obvezo ali prekrijete s sterilno gazo.
For the full list of all side effects reported with Altargo, see the Package 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila
(Invented) name 
(Izmišljen o) ime
This summary was last updated in 06.2013. 
Povzetek je bil nazadnje posodobljen dne 06.2013.
These reactions are usually mild to moderate and temporary. 
Ti odzivi so ponavadi blagi do zmerni in začasni.
The tablets are given every other day, with or without food. 
Tablete se dajejo vsak drugi dan, s hrano ali brez nje.
It is available as tablets: 10 mg (blue), 15 mg (orange) and 50 mg (red). 
Na voljo je v obliki tablet: 10 mg (modre barve), 15 mg (oranžne barve) in 50 mg (rdeče barve).
The duration of treatment depends on the dog's response to treatment. 
Trajanje zdravljenja je odvisno od odziva psa na zdravljenje.
The European Commission granted a marketing authorisation valid throughout the European Union, for Palladia on 23.09.2009. 
Evropska komisija je dovoljenje za promet z zdravilom Palladia, veljavno po vsej Evropski uniji, odobrila dne 23.09.2009.
The usual dose is 3.25 mg per kilogram bodyweight, and the number of tablets to use is carefully calculated for each dog. 
Običajni odmerek je 3,25 mg na kilogram telesne mase, število uporabljenih tablet pa je treba za vsakega psa pazljivo izračunati.
Other information about Palladia: 
Druge informacije o zdravilu Palladia:
The main study was carried out in two phases in 151 dogs with mast cell tumours. 
Glavna študija je bila izvedena v dveh fazah pri 151 psih s tumorji mastocitov.
The tablets must be given whole and should not be divided, broken or ground up. 
Tablete se morajo dajati cele, ne smejo se razdeliti, prelomiti ali zdrobiti.
Treatment started with the recommended dose, but this dose was later reduced or treatment interrupted for a few days in some dogs. 
Zdravljenje se je začelo s priporočenim odmerkom, vendar se je ta odmerek kasneje zmanjšal ali pa je bilo zdravljenje pri nekaterih psih za nekaj dni prekinjeno.
Dogs should be regularly monitored for side effects by the veterinarian (at the beginning of treatment, this should be at least once per week). 
Neželene učinke pri psih naj redno spremlja veterinar (na začetku zdravljenja najmanj enkrat tedensko).
If broken tablets, or the vomit, urine or faeces of a treated dog comes into contact with the skin or eyes, rinse immediately with plenty of water. 
Če prelomljene tablete, izbljuvki, seč ali blato zdravljenega psa pridejo v stik s kožo ali očmi, jih takoj izperite z veliko vode.
After six weeks (second phase), the study continued with all the remaining dogs receiving Palladia for an average of another four and a half months. 
Po šestih tednih (druga faza) se je študija nadaljevala z vsemi preostalimi psi, ki so prejemali zdravilo Palladia povprečno naslednje štiri mesece in pol.
In case of side effects, the veterinarian might decide to lower the dose of Palladia or to stop treatment, either temporarily or permanently. 
Ob neželenih učinkih se lahko veterinar odloči zmanjšati odmerek zdravila Palladia ali zdravljenje prekiniti, bodisi začasno ali stalno.
A number of studies with Palladia were carried out either in laboratory dogs or in animal patients in veterinary practices or hospitals. 
Številne študije so bile izvedene bodisi z laboratorijskimi psi ali z bolnimi živalmi v veterinarskih ambulantah ali bolnišnicah.
The main measures of effectiveness were the ‘objective response' (an evaluation by the veterinarian of the way the tumour changed during treatment) and the time taken until the tumour started to get worse. 
Glavno merilo učinkovitosti je bil „objektivni odziv“ (veterinarska presoja spremembe tumorja med zdravljenjem) in čas, ki je bil potreben za začetek napredovanja tumorja.
These enzymes can be found in mastcell tumours, where they are involved in the growth and spread of cancer cells, and the growth of blood vessels. 
Ti encimi se nahajajo v mastocitnih tumorjih, kjer sodelujejo pri rasti in širjenju rakavih celic in rasti krvnih žil.
If the disease was getting worse, treatment with Palladia was stopped and the dog was taken out of the study. 
Če se je bolezen poslabšala, so zdravljenje z zdravilom Palladia prekinili in psa izključili iz študije.
What benefit has Palladia shown during the studies? 
Kakšne koristi je zdravilo Palladia izkazalo med študijami?
The most common side effects with Palladia are diarrhoea and vomiting, loss of appetite, lethargy (lack of energy), neutropenia (low white blood cell counts), difficulty moving (lameness) and weight loss. 
Najpogostejši neželeni učinki zdravila Palladia so driska in bruhanje, izguba teka, letargija (pomanjkanje energije), nevtropenija (majhno število belih krvnih celic), težave s premikanjem (ohromelost) in izguba telesne mase.
By blocking these enzymes, Palladia can help to control abnormal cell growth and prevent further development of this type of tumour. 
Zdravilo Palladia lahko z zaviranjem teh encimov pomaga nadzirati neobičajno rast celic in preprečuje nadaljnji razvoj te vrste tumorja.
It is used for tumours that are severe in character (grade 2 or 3), have come back, and cannot be removed with surgery. 
Uporablja se pri tumorjih v resni obliki (stopnje II ali III), ki so se ponovili in jih ni mogoče kirurško odstraniti.
It should not be used in dogs that may be hypersensitive (allergic) to toceranib or any of the other ingredients. 
Ne sme se uporabljati pri psih, ki so preobčutljivi za (alergične na) toceranib ali katero koli drugo sestavino zdravila.
Palladia must not be used in dogs less than two years of age or weighting less than 3 kg, in bitches that are pregnant or lactating, or in dogs intended for breeding. 
Zdravilo Palladia se ne sme uporabljati pri psih, mlajših od dveh let, ki tehtajo manj kot tri kg, psicah, ki so breje ali dojijo, ali psih, ki so namenjeni za razplod.
It must not be used in dogs with bleeding in the stomach or gut. 
Ne sme se uporabljati pri psih s krvavitvami v želodcu ali črevesju.
For a full list of all side effects or precautions, see the Package Leaflet. 
Za celoten seznam vseh neželenih učinkov in previdnostnih ukrepov glejte navodilo za uporabo.
What is the risk associated with Palladia? 
Kakšna tveganja so povezana z zdravilom Palladia?
Palladia is used to treat dogs with mast-cell tumours (a type of skin cancer). 
Zdravilo Palladia se uporablja za zdravljenje psov s tumorji mastocitov (vrsto kožnega raka).
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Palladia exceed the risks for the treatment of non-resectable Patnaik grade II (intermediate grade) or III (high grade), recurrent, cutaneous mast cell tumours in dogs and recommended that Palladia be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je sklenil, da so koristi zdravila Palladia pri zdravljenju kirurško neodstranljivih mastocitnih tumorjev stopnje II (srednje stopnje) ali III (visoke stopnje), ponovljivih podkožnih mastocitnih tumorjev pri psih večje od z njim povezanih tveganj ter priporočil, da se za zdravilo Palladia odobri dovoljenje za promet.
In a first phase (up to six weeks), Palladia was compared with placebo (a dummy treatment). 
V prvi fazi (do šestih tednov) so zdravilo Palladia primerjali s placebom (zdravilom brez zdravilne učinkovine).
For Palladia-treated dogs, it also took longer for the tumour to get worse (nine to ten weeks on average) than in those receiving placebo (three weeks on average). 
Prav tako je pri psih, zdravljenih z zdravilom Palladia, trajalo dlje, preden je tumor napredoval (povprečno devet do deset tednov), kot pri tistih, ki so prejemali placebo (v povprečju tri mesece).
If Palladia is taken accidentally, seek medical advice immediately and show the Package Leaflet or the label to the doctor. 
Če ste zdravilo Palladia nenamerno zaužili, nemudoma poiščite zdravniško pomoč in zdravniku pokažite navodilo za uporabo ali ovojnino.
The benefit-risk balance may be found in module 6 of this EPAR. 
Za razmerje med koristmi in tveganji glejte modul 6 tega evropskega javnega poročila o oceni zdravila (EPAR).
Why has Palladia been approved? 
Zakaj je bilo zdravilo Palladia odobreno?
Palladia contains toceranib, which belongs to a class of medicines with anticancer activity. 
Zdravilo Palladia vsebuje toceranib, ki spada v razred zdravil s protirakavim delovanjem.
The active substance in Palladia, toceranib, is a receptor tyrosine kinase inhibitor. 
Zdravilna učinkovina v zdravilu Palladia, toceranib, je zaviralec receptorjev tirozin kinaze.
Dogs treated with Palladia had greater objective response rates (37%) than dogs treated with placebo (8%) after six weeks of treatment. 
Po šestih tednih so bile pri psih, zdravljenih z zdravilom Palladia, objektivne stopnje odziva višje (37 %) kot pri psih, ki so bili zdravljeni s placebom (8 %).
Children should not have close contact with the medicine, or with the faeces or vomit of treated dogs. 
Otroci ne smejo priti v stik z zdravilom, blatom ali izbljuvki zdravljenih psov.
A complete response (disappearance of the tumour) was seen in around 8% and a partial response (shrinkage of the tumour) was seen in around 29% of the dogs treated with Palladia. 
Pri približno 8 % psov, zdravljenih z zdravilom Palladia, je bil odziv popoln (izginotje tumorja), približno 29 % psov pa se je na zdravljenje delno odzvalo (skrčenje tumorja).
What is Palladia used for? 
Za kaj se zdravilo Palladia uporablja?
How has Palladia been studied? 
Kako je bilo zdravilo Palladia raziskano?
How does Palladia work? 
Kako zdravilo Palladia deluje?
What is Palladia? 
Kaj je zdravilo Palladia?
Date of first authorisation: 17 July 2015 
Datum prve odobritve: 17. julij 2015
- Your doctor will decide how many treatments you need. 
- Zdravnik bo določil, koliko zdravljenj potrebujete.
30 minutes. 
30 minut.
Otherwise treatment should be discontinued. 
V nasprotnem primeru je treba zdravljenje ukiniti.
*p-Value is nominal. 
*vrednost p je nominalna.
Currently available data are described in sections 4.8, 5.1 and 5.2. 
Podatki, ki so trenutno na voljo, so opisani v poglavjih 4.8, 5.1 in 5.2.
It is important that you keep this Alert Card and show it to your partner or caregivers. 
Pomembno je, da to opozorilno kartico shranite in jo pokažete partnerju ali skrbniku.
They may occur if you had this kind of transplant in the past or if you get it in the future. 
Lahko se pojavijo v primeru, če ste imeli tako presaditev v preteklosti ali jo boste imeli v prihodnosti.
- It is very important that you do not miss a dose of this medicine. 
- Zelo pomembno je, da ne izpustite odmerka tega zdravila.
These complications can be severe and can lead to death. 
Ti zapleti so lahko hudi in lahko povzročijo smrt.
- If you are taking, have recently taken or might take any other medicines. 
- če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Since it is known that antibodies can be secreted in human milk, a risk to the newborns/infants cannot be excluded. 
Ker pa je znano, da se protitelesa lahko izločajo v materino mleko, tveganja za novorojence/otroke ne moremo izključiti.
These results should be interpreted in the context of the open-label study design and therefore taken cautiously. 
Te rezultate je treba tolmačiti v okviru odprtega načrta študije in jih torej previdno obravnavati.
6 weeks. 
3 tedne.
It is available in cartons containing one glass vial. 
Na voljo je v škatlah, ki vsebujejo eno stekleno vialo.
Data from these patients are too limited to draw any conclusion on safety or efficacy in this population. 
Podatkov pri teh bolnikih je premalo, da bi lahko podali zaključke glede varnosti in učinkovitosti v tej populaciji.
It is important that you also read the package leaflets for these other medicines. 
Pomembno je, da preberete tudi navodila za uporabo teh drugih zdravil.
The patient educational material should contain: 
Izobraževalno gradivo za bolnike mora vsebovati:
The KEYNOTE-426 trial was not powered to evaluate efficacy of individual subgroups. 
Moč preskušanja KEYNOTE-426 ni bila zadostna za ocenjevanje učinkovitosti po posameznih podskupinah.
Patients without disease progression could be treated for up to 24 months. 
Bolnike brez napredovanja bolezni so lahko zdravili do 24 mesecev.
All but two patients were white. 
Vsi bolniki razen dveh so bili belci.
The following terms represent a group of related events that describe a medical condition rather than a single event. 
Naslednji izrazi predstavljajo skupino sorodnih učinkov, ki opisujejo zdravstveno stanje, ne enega posameznega učinka.
The management guidelines for these adverse reactions are described in section 4.4. 
Navodila za ukrepanje pri teh neželenih učinkih so opisana v poglavju 4.4.
Allow up to 5 minutes for the bubbles to clear. 
Pustite do 5 minut, da izginejo mehurčki.
ATC code: L01XC18 
Oznaka ATC: L01XC18
A total of 559 patients were randomised. 
Skupno je bilo randomiziranih 559 bolnikov.
Not reached 
ni doseženo
A total of 861 patients were randomised. 
V celoti je bilo randomiziranih 861 bolnikov.
Hyperthyroidism may be managed symptomatically. 
Hipertiroidizem je mogoče obvladovati simptomatsko.
Control: 
kontrola:
Common severe skin reactions s, 
Pogosti hude kožne reakcije s,
Efficacy results based on an additional seven months of follow-up are summarized in Table 10 and Figure 4. 
Rezultati učinkovitosti na podlagi dodatnih sedmih mesecev spremljanja so povzeti v preglednici 10 in na sliki 4.
Children and adolescents KEYTRUDA should not be used in children and adolescents below 18 years of age. 
Otroci in mladostniki Zdravila KEYTRUDA se ne sme uporabljati pri otrocih in mladostnikih, mlajših od 18 let.
Standard Treatment: 
standardno zdravljenje:
Chemistry and haematology laboratory tests were performed at each cycle. 
Biokemične in hematološke laboratorijske preiskave so bile opravljene v vsakem ciklusu.
• To avoid foaming, deliver the water along the walls of the vial and not directly on the lyophilised powder. 
• Za preprečitev penjenja vodo dodajte ob steni viale, ne neposredno na liofiliziran prašek.
OS results are reported from the final analysis at a median follow-up of 25 months. 
O rezultatih OS so poročali iz končne analize pri medianem času spremljanja 25 mesecev.
The Card reminds patients about key symptoms that need to be reported immediately to the physician/nurse. 
Kartica bolnike opomni na ključne simptome, o katerih morajo takoj obvestiti zdravnika/medicinsko sestro.
Number (% 
število (%
Frequencies are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); and not known (cannot be estimated from the available data). 
Pogostnosti so opredeljene kot: zelo pogosti (≥ 1/10), pogosti (od ≥ 1/100 do < 1/10), občasni (od ≥ 1/1.000 do < 1/100), redki (od ≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
Patient-reported outcomes (PROs) were assessed using EORTC QLQ-C30. 
Izidi po navedbi bolnikov (PRO - patient-reported outcome) so bili ocenjeni z uporabo EORTC QLQ-C30.
All but one patient was white. 
Vsi bolniki razen enega so bili belci.
The value of biomarkers to predict the efficacy of pembrolizumab should be further explored, specifically: 
Pomen biomarkerjev za napoved učinkovitosti pembrolizumaba je treba še naprej raziskovati, točneje:
When assessing the PD-L1 status of the tumour, it is important that a well-validated and robust methodology is chosen to minimise false negative or false positive determinations. 
Pri ocenjevanju statusa PD-L1 tumorja je pomembno izbrati dobro validirano in robustno metodologijo, da bi čim bolj zmanjšali možnost lažno negativnih ali lažno pozitivnih določitev.
PFS and ORR results are reported from an interim analysis at a median follow-up of 11 months. 
O rezultatih PFS in ORR so poročali iz vmesne analize pri medianem času spremljanja 11 mesecev.
The exposure multiple between the NOAEL and a human dose of 200 mg was 74. 
Večkratnik izpostavljenosti med NOAEL in odmerkom 200 mg pri človeku je bil 74.
Your doctor may give you other medicines in order to prevent more severe complications and reduce your symptoms. 
Zdravnik vam lahko predpiše druga zdravila, da bi preprečil hujše zaplete in omilil simptome.
Based on Kaplan-Meier estimation 
Na podlagi Kaplan-Meierjeve ocene
BRAF mutations were reported in 13% of the study population. 
Mutacije BRAF so bile ugotovljene pri 13 % študijske populacije.
These side effects can sometimes become life-threatening and can lead to death. 
Ti neželeni učinki lahko včasih postanejo življenjsko nevarni in lahko povzročijo smrt.
The educational programme is aimed at increasing the awareness of patients and/or their caregivers on the signs and symptoms relevant to the early recognition/identification of the potential immunerelated adverse reactions (irARs). 
Namen izobraževalnega programa je povečati ozaveščenost bolnikov in/ali njihovih skrbnikov o znakih in simptomih, pomembnih za zgodnje odkrivanje/prepoznavanje možnih imunsko pogojenih neželenih učinkov.
You will also find this information in the Patient Alert Card you have been given by your doctor. 
To informacijo boste našli tudi v opozorilni kartici, ki jo boste prejeli pri zdravniku.
These side effects may happen anytime during treatment or even after your treatment has ended. 
Ti neželeni učinki se lahko pojavijo kadar koli med zdravljenjem ali celo po koncu zdravljenja.
• Do not co-administer other medicinal products through the same infusion line. 
• Tega zdravila po isti infuzijski liniji ne dajajte skupaj z drugimi zdravili.
Immune-related adverse reactions affecting more than one body system can occur simultaneously. 
Imunsko pogojeni neželeni učinki, ki prizadenejo več organskih sistemov, se lahko pojavijo hkrati.
• Data on RNA and proteomic serum profiling 
• Podatki o profilu RNA in proteomskem serumu
Both studies included patients regardless of PD-L1 expression. 
V obe študiji so bili vključeni bolniki ne glede na izraženost PD-L1.
Efficacy results are summarized in Table 18. 
Rezultati učinkovitosti so povzeti v preglednici 18.
11.3 (10.8, Not reached) 
11,3 (10,8; ni dosežena)
TPS 1 to 49% 
TPS 1 do 49 %